Amgen Inc. (AMGN) Given New $188.00 Price Target at Royal Bank Of Canada

Amgen Inc. (NASDAQ:AMGN) had its target price decreased by research analysts at Royal Bank Of Canada from $192.00 to $188.00 in a report released on Thursday, October 26th, MarketBeat.com reports. The brokerage currently has a “sector perform” rating on the medical research company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 9.08% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 price target on the stock. in a report on Friday, July 21st. They noted that the move was a valuation call. Credit Suisse Group reiterated a “neutral” rating and issued a $186.00 price target (up previously from $177.00) on shares of Amgen in a report on Friday, September 29th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and issued a $203.00 price target on shares of Amgen in a report on Thursday, September 7th. Morgan Stanley reiterated an “overweight” rating and issued a $196.00 price target (up previously from $189.00) on shares of Amgen in a report on Friday, October 6th. Finally, UBS AG set a $180.00 target price on Amgen and gave the stock a “hold” rating in a report on Wednesday, July 26th. Thirteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $190.03.

Amgen (NASDAQ:AMGN) opened at $172.35 on Thursday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen has a 12 month low of $138.83 and a 12 month high of $191.10. The stock has a market capitalization of $125,110.70, a price-to-earnings ratio of 13.70, a price-to-earnings-growth ratio of 2.50 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.02 earnings per share. equities analysts anticipate that Amgen will post 12.66 EPS for the current fiscal year.

Amgen declared that its board has approved a share repurchase program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company’s board believes its shares are undervalued.

WARNING: “Amgen Inc. (AMGN) Given New $188.00 Price Target at Royal Bank Of Canada” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://ledgergazette.com/2017/11/13/amgen-inc-amgn-pt-lowered-to-188-00.html.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Camelot Portfolios LLC bought a new stake in shares of Amgen in the 1st quarter valued at about $1,429,000. PGGM Investments grew its position in shares of Amgen by 2.3% in the 2nd quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock valued at $115,555,000 after buying an additional 15,059 shares during the last quarter. Shelton Capital Management grew its position in shares of Amgen by 82.7% in the 1st quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock valued at $17,883,000 after buying an additional 49,354 shares during the last quarter. Greylin Investment Mangement Inc. grew its position in shares of Amgen by 466.9% in the 2nd quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock valued at $2,416,000 after buying an additional 11,555 shares during the last quarter. Finally, Kelman Lazarov Inc. grew its position in shares of Amgen by 8.2% in the 2nd quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock valued at $272,000 after buying an additional 120 shares during the last quarter. Hedge funds and other institutional investors own 78.20% of the company’s stock.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply